Overview of the impact of conventional systemic therapies on breast cancer.
AffiliationCRUK Department of Medical Oncology, University of Manchester, Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX, UK. Anthony.Howell@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractSurvival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.
CitationOverview of the impact of conventional systemic therapies on breast cancer. 2005, 12 Suppl 1:S9-S16 Endocr. Relat. Cancer
- Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
- Authors: Emens LA
- Issue date: 2005 May-Jun
- Controversies in breast cancer: adjuvant and neoadjuvant therapy.
- Authors: Montemurro F, Redana S, Valabrega G, Aglietta M
- Issue date: 2005 Jun
- Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
- Authors: Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F
- Issue date: 2007 Mar
- Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells.
- Authors: Cavaliere C, Corvigno S, Galgani M, Limite G, Nardone A, Veneziani BM
- Issue date: 2010 Jul
- Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies revisited.
- Authors: Bartelink H
- Issue date: 2007 Dec